Monitoring and Evaluation Consultancy in Nigeria about Education, Food and Nutrition and Water Sanitation Hygiene, requiring 5-9 years of experience, from Save the Children; closing on 28 May 2021
Monitoring and Evaluation Consultancy in Nigeria about Food and Nutrition, requiring 5-9 years of experience, from Save the Children; closing on 28 May 2021
Telix Pharmaceuticals Limited: Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration (TGA) to commence a Phase III clinical trial of the Company s PSMA
1 targeted prostate cancer therapy candidate TLX591 (
177Lu-DOTA-rosopatamab), in patients with advanced metastatic castrate-resistant prostate cancer (mCRPC).
The Phase III ProstACT trial is an international, multi-centre, randomised controlled trial (RCT) in patients with PSMA-expressing mCRPC, experiencing disease progression following prior treatment with a novel androgen axis drug (NAAD). The ProstACT trial will enrol approximately 390 patients and incorporates patient selection using
Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration (TGA) to commence a Phase III clinical trial of the Company’s PSMA
1 targeted prostate cancer therapy candidate TLX591 (
177Lu-DOTA-rosopatamab), in patients with advanced metastatic castrate-resistant prostate cancer (mCRPC).
The Phase III “ProstACT” trial is an international, multi-centre, randomised controlled trial (RCT) in patients with PSMA-expressing mCRPC, experiencing disease progression following prior treatment with a novel androgen axis drug (NAAD). The ProstACT trial will enrol approximately 390 patients and incorporates patient selection using
Background
A local coronavirus disease 2019 (COVID-19) case confirmed on June 11, 2020 triggered an outbreak in Beijing, China after 56 consecutive days without a newly confirmed case. Non-pharmaceutical interventions (NPIs) were used to contain the source in Xinfadi (XFD) market. To rapidly control the outbreak, both traditional and newly introduced NPIs including large-scale management of high-risk populations and expanded severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR-based screening in the general population were conducted in Beijing. We aimed to assess the effectiveness of the response to the COVID-19 outbreak in Beijing’s XFD market and inform future response efforts of resurgence across regions.
Methods